尤瑞克林对急性缺血性脑卒中患者疗效和血浆内皮素-1的影响

The influence of urinarykallid on plasma endothelin-1 and treatment effect of acute ischemicstroke patients

目的探讨尤瑞克林对急性缺血性脑卒中患者的疗效及对其血浆内皮素-1(ET-1)的影响。方法选取急性缺血性脑卒中患者120例为研究对象,对照组与观察组分别60例。对照组予降脂、抗血小板聚集及改善脑循环等基础治疗,观察组在此基础上予注射用尤瑞克林0.15 PNA治疗,观察临床疗效,分别于治疗前、治疗第14天测定血浆ET-1浓度,进行神经功能缺损程度(NIHSS)评分。结果观察组的显效率为66.67%,总有效率为85.00%;对照组分别为36.67%及58.33%。2组患者治疗前的血浆ET-1浓度、NIHSS评分差异无统计学意义(P>0.05);治疗14 d后,ET-1浓度及NIHSS评分均有所下降,观察组的下降程度较对照组显著(P<0.01)。结论与基础治疗相比,加用尤瑞克林治疗急性缺血性脑卒中患者安全有效,可以更显著地降低其血浆ET-1浓度,促进神经功能恢复,其作用机制可能是通过患者血浆ET-1的浓度而发挥作用。

Objective To explore the influence of urinarykallid on treatment effect of patients with acute ischemic stroke and plasma endothelin-1 （ET-1）.Methods A total of 120 patients with acute ischemic stroke were enrolled and divided into control group and observation group.Control group was given basic treatment including reducing lipid,anti-platelet aggregation and improving brain circulation and observation group was given urinarykallid based on control group.Clinical efficacy was observed and plasma ET-1 was tested before treatment and neural function deficiency score was performed on 14th day according to National Institutes of Health Stroke Scale （NIHSS）.Results Overall response rate （ORR） in observation group and control group were 85.00％ and 58.33％,respectively.Plasma ET-1 concentration and NIHSS scores between 2 groups before treatment were not significant （P ＞0.05）,but decreased after treatment of 14 d and observation group were more significant than control group （P ＜ 0.O1）.Conclusion Compared with basic treatment,urinarykallid was more safe and effective in treatment of acute ischemic stroke,it can markedly lower plasma ET-1 concentration and improve recovery of neural function with the mechanism of plasma ET-1 concentration alternation.